Mobilization of allogeneic peripheral blood stem cell donors with intravenous plerixafor mobilizes a unique graft
Year: 2017
Type: article
Abstract: /kg recipient weight in 1 apheresis collection to ≤10% was not reached. The failure rate was 34%. Studies evaluating the stem cell phenotype and gene expression revealed a novel plasmacytoid dendritic cell precursor preferentially mobilized by plerixafor with high interferon-α producing ability. The observed cytomegalovirus (CMV) viremia rate for patients at risk was low (15%), as were the rates of acute grade 2-4 graft-versus-host disease (GVHD) (21%). Day 100 treatment related mortality was low (3%). In conclusion, plerixafor results in rapid stem cell mobilization regardless of route of administration and resulted in novel cellular composition of the graft and favorable recipient outcomes. These trials were registered at clinicaltrials.gov as #NCT00241358 and #NCT00914849.
Source: Blood
Authors: Mark A. Schroeder, Michael P. Rettig, Sandra Lopez, Stephanie Christ, Mark Fiala, William Eades, Fazia A. Mir, Jin Shao, Kyle McFarland, Kathryn Trinkaus, William Shannon, Elena Deych, Jinsheng Yu, Ravi Vij, Keith Stockerl-Goldstein, Amanda F. Cashen, Geoffrey L. Uy, Camille N. Abboud, Peter Westervelt, John F. DiPersio
Institutions: Washington University in St. Louis, Saint Louis University
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: green
Awards: OPTIMIZING ALLOGENEIC TRANSPLANTATION USING CXCR4 BLOCKADE, TARGETING THE CXCR4-SDF1 AXIS AS THERAPY FOR RELAPSED/REFRACTORY AML, Washington University Institute of Clinical and Translational Sciences, TARGETING AML-STROMAL INTERACTIONS, BM NICHE DISRUPTION AND IMMUNOTHERAPY IN HEMATOLOGICAL MALIGNANCIES, Cancer Center Support Grant
OpenAlex ID: W2606681743